GNU social JP
  • FAQ
  • Login
GNU social JPは日本のGNU socialサーバーです。
Usage/ToS/admin/test/Pleroma FE
  • Public

    • Public
    • Network
    • Groups
    • Featured
    • Popular
    • People

Embed Notice

HTML Code

Corresponding Notice

  1. Embed this notice
    Jeff "never puts away anything, especially oven mitts" Cliff, Bringer of Nightmares 🏴‍☠️🦝🐙 🇱🇧🧯 🇨🇦🐧 (jeffcliff@shitposter.world)'s status on Sunday, 13-Apr-2025 02:17:31 JSTJeff "never puts away anything, especially oven mitts" Cliff,  Bringer of Nightmares 🏴‍☠️🦝🐙 🇱🇧🧯 🇨🇦🐧Jeff "never puts away anything, especially oven mitts" Cliff, Bringer of Nightmares 🏴‍☠️🦝🐙 🇱🇧🧯 🇨🇦🐧
    in reply to
    • 𝅙𝅙𝅙𝅙𝅙𝅙𝅙𝅙
    @sally

    >They are shit, if a vaccine has the chance to cause you a stroke and irreversibly turn you braindead,

    ALL vaccines can do probably this. Just like ALL vaccines can and do kill some people who take them. But the thing is - strokes after vaccines are *very* rare,
    rare enough to justify that risk when dealing with a disease that can do much worse. And in particular, and they are *not* very rare in diseases like covid. So not rare that the vaccines actually reduce the chance of stroke in populations who take them even after considering the vaccine-caused-events. https://heart.bmj.com/content/110/9/635

    > ruining the rest of your life until you die, then it's potentially shit, specially if it's mandatory by government and specially if such government doesn't warn you about it.

    Not sure what government(germany??) is in question but for mandatory government vaccines they should absolutely have a program to deal with vaccine injured people in this case. Canada & the US both have such programs. It's a tragedy and there's no getting around that but nowhere near the scale of the tragedy of covid itself (which is still going on because to a large degree not enough people got vaccinated)
    In conversationabout a month ago from shitposter.worldpermalink

    Attachments

    1. Domain not in remote thumbnail source whitelist: heart.bmj.com
      The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications
      Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0–30, 31–90, 91–180 and 181–365 days. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were conducted across staggered cohorts and databases. Results The study included 10.17 million vaccinated and 10.39 million unvaccinated people. Vaccination was associated with reduced risks of acute (30-day) and post-acute COVID-19 VTE, ATE and HF: for example, meta-analytic sHR of 0.22 (95% CI 0.17 to 0.29), 0.53 (0.44 to 0.63) and 0.45 (0.38 to 0.53), respectively, for 0–30 days after SARS-CoV-2 infection, while in the 91–180 days sHR were 0.53 (0.40 to 0.70), 0.72 (0.58 to 0.88) and 0.61 (0.51 to 0.73), respectively. Conclusions COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes. These effects were more pronounced for acute COVID-19 outcomes, consistent with known reductions in disease severity following breakthrough versus unvaccinated SARS-CoV-2 infection. Data may be obtained from a third party and are not publicly available. CPRD: CPRD data were obtained under the CPRD multi-study license held by the University of Oxford after Research Data Governance (RDG) approval. Direct data sharing is not allowed. SIDIAP: In accordance with current European and national law, the data used in this study is only available for the researchers participating in this study. Thus, we are not allowed to distribute or make publicly available the data to other parties. However, researchers from public institutions can request data from SIDIAP if they comply with certain requirements. Further information is available online () or by contacting SIDIAP (sidiap@idiapjgol.org). CORIVA: CORIVA data were obtained under the approval of Research Ethics Committee of the University of Tartu and the patient level data sharing is not allowed. All analyses in this study were conducted in a federated manner, where analytical code and aggregated (anonymised) results were shared, but no patient-level data was transferred across the collaborating institutions.
  • Help
  • About
  • FAQ
  • TOS
  • Privacy
  • Source
  • Version
  • Contact

GNU social JP is a social network, courtesy of GNU social JP管理人. It runs on GNU social, version 2.0.2-dev, available under the GNU Affero General Public License.

Creative Commons Attribution 3.0 All GNU social JP content and data are available under the Creative Commons Attribution 3.0 license.

Embed this notice